figshare
Browse
s41598-017-18645-8.pdf (1.91 MB)

Flavin Reductase Contributes to Pneumococcal Virulence by Protecting from Oxidative Stress and Mediating Adhesion and Elicits Protection Against Pneumococcal Challenge.

Download (1.91 MB)
journal contribution
posted on 2018-01-25, 16:25 authored by Giora I. Morozov, Nurith Porat, Tatyana Kushnir, Hastyar Najmuldeen, Asad Adawi, Vered Chalifa-Caspi, Rachel Benisty, Ariel Ohayon, Ofir Liron, Shalhevet Azriel, Itai Malka, Shahar Dotan, Maxim Portnoi, Andrew A. Piotrowski, Daniel Kafka, Barak Hajaj, Tali Fishilevich, Marilou Shagan, Michael Tal, Ron Ellis, Donald A. Morrison, Andrea M. Mitchell, Timothy J. Mitchell, Ron Dagan, Hasan Yesilkaya, Yaffa Mizrachi Nebenzahl
Pneumococcal flavin reductase (FlaR) is known to be cell-wall associated and possess age dependent antigenicity in children. This study aimed at characterizing FlaR and elucidating its involvement in pneumococcal physiology and virulence. Bioinformatic analysis of FlaR sequence identified three-conserved cysteine residues, suggesting a transition metal-binding capacity. Recombinant FlaR (rFlaR) bound Fe2+ and exhibited FAD-dependent NADP-reductase activity, which increased in the presence of cysteine or excess Fe2+ and inhibited by divalent-chelating agents. flaR mutant was highly susceptible to H2O2 compared to its wild type (WT) and complemented strains, suggesting a role for FlaR in pneumococcal oxidative stress resistance. Additionally, flaR mutant demonstrated significantly decreased mice mortality following intraperitoneal infection. Interestingly, lack of FlaR did not affect the extent of phagocytosis by primary mouse peritoneal macrophages but reduced adhesion to A549 cells compared to the WT and complemented strains. Noteworthy are the findings that immunization with rFlaR elicited protection in mice against intraperitoneal lethal challenge and anti-FlaR antisera neutralized bacterial virulence. Taken together, FlaR's roles in pneumococcal physiology and virulence, combined with its lack of significant homology to human proteins, point towards rFlaR as a vaccine candidate.

Funding

This work was supported by grants from the Israeli Ministry of Health numbers 4776 and 5540, 3000003867, from the Center of Emerging Diseases #2506, from the Israel Academy of Science 613/04, Te Israel Ministry of Commerce and Industry to NasVax Ltd., European Community 7th FP: CAREPNEUMO 223111, from BGNegev Biotechnology to YMN.

History

Citation

Scientific Reports , 2018, 8 (1), 314

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation

Version

  • VoR (Version of Record)

Published in

Scientific Reports

Publisher

Nature Publishing Group

issn

2045-2322

eissn

2045-2322

Acceptance date

2017-11-01

Copyright date

2017

Available date

2018-01-25

Publisher version

https://www.nature.com/articles/s41598-017-18645-8

Notes

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-18645-8.

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC